Brief: Alphamab Oncology Announces Transactions With Pathos AI For JSKN016
04/08/2026 02:35
BRIEF-Alphamab Oncology Announces Transactions With Pathos AI For JSKN016 Aug 4 (Reuters) - Alphamab Oncology 9966.HK:
TRANSACTIONS WITH PATHOS AI FOR JSKN016
JIANGSU ALPHAMAB TO RECEIVE $125 MILLION UPFRONT, UP TO $2.09 BILLION TOTAL FROM PATHOS AI
UNIT GRANTED PATHOS AI EXCLUSIVE LICENSE TO COMMERCIALIZE JSKN016 IN TERRITORIES OUTSIDE CHINESE MAINLAND, HK, MACAU, TAIWAN
Further company coverage: 9966.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alphamab Oncology
See all newsBrief: Alphamab Oncology Says Fei Wang Resigns As Chief Financial Officer
Brief: Alphamab Oncology Says First Patient Dosed In Phase III Clinical Study Of JSKN033 Monotherapy For Treatment Of Cervical Cancer
Brief: Alphamab Oncology Says Board Resolves To Repurchase Shares Up To HK$80 Million In Value
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab With HB1801 For Her2+ Advanced Breast Cancer
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab (KN026)